Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 47

1.

Beyond the Lungs: Systemic Manifestations of Pulmonary Arterial Hypertension.

Nickel NP, Yuan K, Dorfmuller P, Provencher S, Lai YC, Bonnet S, Austin ED, Koch CD, Morris A, Perros F, Montani D, Zamanian RT, de Jesus Perez VA.

Am J Respir Crit Care Med. 2019 Sep 12. doi: 10.1164/rccm.201903-0656CI. [Epub ahead of print]

PMID:
31513751
2.

Conformational Effects of Pt-Shells on Nanostructures and Corresponding Oxygen Reduction Reaction Activity of Au-Cluster-Decorated NiOx@Pt Nanocatalysts.

Bhalothia D, Fan YJ, Lai YC, Yang YT, Yang YW, Lee CH, Chen TY.

Nanomaterials (Basel). 2019 Jul 11;9(7). pii: E1003. doi: 10.3390/nano9071003.

3.

Loss of GCN5L1 in cardiac cells limits mitochondrial respiratory capacity under hyperglycemic conditions.

Thapa D, Zhang M, Manning JR, Guimarães DA, Stoner MW, Lai YC, Shiva S, Scott I.

Physiol Rep. 2019 Apr;7(8):e14054. doi: 10.14814/phy2.14054.

4.

TAKling GDF-15 and skeletal muscle atrophy in pulmonary hypertension: are we there yet?

Lai YC, Provencher S, Goncharova EA.

Thorax. 2019 Feb;74(2):103-105. doi: 10.1136/thoraxjnl-2018-212680. Epub 2018 Dec 15. No abstract available.

PMID:
30554140
5.

Insights into the pulmonary vascular complications of heart failure with preserved ejection fraction.

Lai YC, Wang L, Gladwin MT.

J Physiol. 2019 Feb;597(4):1143-1156. doi: 10.1113/JP275858. Epub 2018 Dec 30.

PMID:
30549058
6.

Metformin Therapy for Pulmonary Hypertension Associated with Heart Failure with Preserved Ejection Fraction versus Pulmonary Arterial Hypertension.

Goncharov DA, Goncharova EA, Tofovic SP, Hu J, Baust JJ, Pena AZ, Ray A, Rode A, Vanderpool RR, Mora AL, Gladwin MT, Lai YC.

Am J Respir Crit Care Med. 2018 Sep 1;198(5):681-684. doi: 10.1164/rccm.201801-0022LE. No abstract available.

7.

Emerging therapeutics in pulmonary hypertension.

Hensley MK, Levine A, Gladwin MT, Lai YC.

Am J Physiol Lung Cell Mol Physiol. 2018 May 1;314(5):L769-L781. doi: 10.1152/ajplung.00259.2017. Epub 2018 Feb 1. Review.

8.

Hazardous factors besides infection in hypoglycemia.

Su YJ, Lai YC, Liao CJ.

Biomed Rep. 2017 Apr;6(4):480-484. doi: 10.3892/br.2017.872. Epub 2017 Mar 13.

9.

Polyphosphate metabolism by purple non-sulfur bacteria and its possible application on photo-microbial fuel cell.

Lai YC, Liang CM, Hsu SC, Hsieh PH, Hung CH.

J Biosci Bioeng. 2017 Jun;123(6):722-730. doi: 10.1016/j.jbiosc.2017.01.012. Epub 2017 Mar 11.

PMID:
28291662
10.

Development of a Mouse Model of Metabolic Syndrome, Pulmonary Hypertension, and Heart Failure with Preserved Ejection Fraction.

Meng Q, Lai YC, Kelly NJ, Bueno M, Baust JJ, Bachman TN, Goncharov D, Vanderpool RR, Radder JE, Hu J, Goncharova E, Morris AM, Mora AL, Shapiro SD, Gladwin MT.

Am J Respir Cell Mol Biol. 2017 Apr;56(4):497-505. doi: 10.1165/rcmb.2016-0177OC.

11.

Mouse Genome-Wide Association Study of Preclinical Group II Pulmonary Hypertension Identifies Epidermal Growth Factor Receptor.

Kelly NJ, Radder JE, Baust JJ, Burton CL, Lai YC, Potoka KC, Agostini BA, Wood JP, Bachman TN, Vanderpool RR, Dandachi N, Leme AS, Gregory AD, Morris A, Mora AL, Gladwin MT, Shapiro SD.

Am J Respir Cell Mol Biol. 2017 Apr;56(4):488-496. doi: 10.1165/rcmb.2016-0176OC.

12.

Automated Measurement of Blood Vessels in Tissues from Microscopy Images.

Kelly NJ, Dandachi N, Goncharov DA, Pena AZ, Radder JE, Gregory AD, Lai YC, Leme AS, Gladwin MT, Goncharova EA, St Croix CM, Shapiro SD.

Curr Protoc Cytom. 2016 Oct 10;78:12.44.1-12.44.13. doi: 10.1002/cpcy.10.

14.

SIRT3-AMP-Activated Protein Kinase Activation by Nitrite and Metformin Improves Hyperglycemia and Normalizes Pulmonary Hypertension Associated With Heart Failure With Preserved Ejection Fraction.

Lai YC, Tabima DM, Dube JJ, Hughan KS, Vanderpool RR, Goncharov DA, St Croix CM, Garcia-Ocaña A, Goncharova EA, Tofovic SP, Mora AL, Gladwin MT.

Circulation. 2016 Feb 23;133(8):717-31. doi: 10.1161/CIRCULATIONAHA.115.018935. Epub 2016 Jan 26.

15.

Novel Targets of Drug Treatment for Pulmonary Hypertension.

Hu J, Xu Q, McTiernan C, Lai YC, Osei-Hwedieh D, Gladwin M.

Am J Cardiovasc Drugs. 2015 Aug;15(4):225-34. doi: 10.1007/s40256-015-0125-4. Review.

PMID:
26016608
16.

The evaluation of microbiology and prognosis of fournier's gangrene in past five years.

Tang LM, Su YJ, Lai YC.

Springerplus. 2015 Jan 13;4:14. doi: 10.1186/s40064-014-0783-8. eCollection 2015.

17.

PINK1 deficiency impairs mitochondrial homeostasis and promotes lung fibrosis.

Bueno M, Lai YC, Romero Y, Brands J, St Croix CM, Kamga C, Corey C, Herazo-Maya JD, Sembrat J, Lee JS, Duncan SR, Rojas M, Shiva S, Chu CT, Mora AL.

J Clin Invest. 2015 Feb;125(2):521-38. doi: 10.1172/JCI74942. Epub 2014 Dec 22.

18.

Scavenger receptor function of mouse Fcγ receptor III contributes to progression of atherosclerosis in apolipoprotein E hyperlipidemic mice.

Zhu X, Ng HP, Lai YC, Craigo JK, Nagilla PS, Raghani P, Nagarajan S.

J Immunol. 2014 Sep 1;193(5):2483-95. doi: 10.4049/jimmunol.1303075. Epub 2014 Jul 18.

19.

Pulmonary arterial hypertension: the clinical syndrome.

Lai YC, Potoka KC, Champion HC, Mora AL, Gladwin MT.

Circ Res. 2014 Jun 20;115(1):115-30. doi: 10.1161/CIRCRESAHA.115.301146. Review.

20.

Protocadherin 10 suppresses tumorigenesis and metastasis in colorectal cancer and its genetic loss predicts adverse prognosis.

Jao TM, Tsai MH, Lio HY, Weng WT, Chen CC, Tzeng ST, Chang CY, Lai YC, Yen SJ, Yu SL, Yang YC.

Int J Cancer. 2014 Dec 1;135(11):2593-603. doi: 10.1002/ijc.28899. Epub 2014 Apr 23.

Supplemental Content

Loading ...
Support Center